Nuvation Bio Inc (NUVB) concluded trading on Wednesday at a closing price of $2.24, with 5.55 million shares of worth about $12.42 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.58% during that period and on March 12, 2025 the price saw a loss of about -2.18%. Currently the company’s common shares owned by public are about 336.84M shares, out of which, 226.82M shares are available for trading.
Stock saw a price change of 19.79% in past 5 days and over the past one month there was a price change of -1.75%. Year-to-date (YTD), NUVB shares are showing a performance of -15.79% which decreased to -8.20% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.67 but also hit the highest price of $4.16 during that period. The average intraday trading volume for Nuvation Bio Inc shares is 2.55 million. The stock is currently trading 7.13% above its 20-day simple moving average (SMA20), while that difference is down -6.01% for SMA50 and it goes to -17.74% lower than SMA200.
Nuvation Bio Inc (NYSE: NUVB) currently have 336.84M outstanding shares and institutions hold larger chunk of about 45.77% of that.
The stock has a current market capitalization of $758.64M and its 3Y-monthly beta is at 1.30. It has posted earnings per share of -$2.25 in the same period. It has Quick Ratio of 9.04 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NUVB, volatility over the week remained 13.90% while standing at 8.66% over the month.
Analysts are in expectations that Nuvation Bio Inc (NUVB) stock would likely to be making an EPS of -0.12 in the current quarter, while forecast for next quarter EPS is -0.13 and it is -0.67 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.13 which is -0.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.04 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 73.12% while it is estimated to decrease by -12.85% in next year. EPS is likely to grow at an annualized rate of 37.20% for next 5-years, compared to annual growth of -49.14% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on March 27, 2024 offering a Buy rating for the stock and assigned a target price range of between $1.40 and $10 to it. Coverage by BTIG Research stated Nuvation Bio Inc (NUVB) stock as a Buy in their note to investors on March 26, 2024, suggesting a price target of $5 for the stock. Stock get a Market perform rating from BMO Capital Markets on August 02, 2022.
